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release of a series of suprarenal barbs designed to mimic a
surgical anastomosis.6,10 The endovascular system has
incorporated many modifications to prevent failures that
can be detected during early experiences. The device is
now commercially available in Europe and Australia, and a
phase II Food and Drug Administration trial is under way
in the United States. We anticipate that a careful assess-
ment of accumulated data will provide us with the ability
to modify the system and ensure its safety for the treat-
ment of aortoiliac aneurysms.
MATERIAL AND METHODS
Data were collected from the following early Zenith
implantation sites: the Royal Perth Hospital, Cleveland
Clinic Foundation, University of San Francisco Medical
Center, Malmo-Lund University Hospital, Nottingham,
Frankfurt’s Stadische Kliniken, and the University of
Rochester. A total of 528 patients have been prospectively
enrolled in a variety of database formats at each institu-
tion. Data collected included demographics, comorbid
conditions, aortic morphologic features, device character-
istics, implantation technique, complications, and follow-
up information. Individual patient data was compiled into
a single database. The absence of a concurrent control
group precludes the comparison of the endovascular
The Zenith endograft has evolved from a worldwide
collaborative effort that began in 1991. Observations of
early complications1-6 associated with endovascular graft-
ing have resulted in a series of modifications that led to the
current system. Initial studies in animals7 and
humans2,3,5,8 used prostheses fashioned with Gianturco
Z-stents and Dacron fabric. The implantable portion of
this device has progressed from an unsupported monoiliac
device, to a fully supported modular bifurcated system.
The current delivery system has undergone development
in parallel to the prosthesis.9 Sophisticated mechanisms
allow for fine positioning adjustments and the controlled
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Purpose: To evaluate the initial and mid-term results of the Zenith endovascular grafting system for infrarenal abdomi-
nal aortic aneurysms.
Methods: Prospective databases at seven centers were used to assess a cohort of patients that underwent treatment for
aortic, aortoiliac, or iliac aneurysms since 1995. Data were analyzed to yield descriptive characteristics that pertained to
the patients, the aortic morphologic features, the graft configuration, and the complications. Follow-up imaging data
were used to determine size changes of the aneurysm sac, endoleak rates, and further complications. Finally survival data
were expressed with a Kaplan-Meier analysis.
Results: A total of 528 patients were treated with the Zenith endograft. Most of the patients (66%) were considered to
be at a high physiologic risk for open repair. Successful graft implantation was accomplished in all but four patients. An
overall endoleak rate of 15% was noted, of which 4% was treated urgently because they were thought to represent attach-
ment site faults. The mean follow-up period was 18 months. A total of eight endograft migrations were detected after 2
years of follow-up with an early version of the system. There were three late conversions; two ruptures occurred during
the follow-up period.
Conclusion: This early and mid-term data support the use of the Zenith endovascular graft for the treatment of aortic
and aortoiliac aneurysms in properly selected patients. The risks of significant complications or aneurysm rupture are
low. (J Vasc Surg 2001;33:S157-64.)
cohort to the outcome of patients undergoing open repair.
Morphologic changes were assessed with a chi-squared
analysis. Survival was assessed with a Kaplan-Meier analysis.
The initial group of implanting physicians all had sig-
nificant experience with other endovascular devices prior
to the use of the Zenith graft. Although there were many
similarities between these physician groups, there were
also substantial differences with regard to patient selec-
tion, management, graft design, and follow-up protocols.
However, several fundamental generalizations could be
made regarding patient selection, implantation tech-
niques, and follow-up protocols. Most investigators felt
endovascular grafting should be performed in a physio-
logically high-risk group of patients, particularly with
respect to our early implantations. Aneurysms that were
significantly enlarging or larger than 5 cm were treated,
providing that the arterial anatomy was amenable to
endovascular repair. Devices were only implanted into
patients who had given informed consent for the proce-
dure; and all implantations were performed under
Institutional Review Board approval, if the graft was not
commercially available.
Endograft dimensions and configurations were based
on measurements obtained from a variety of imaging tech-
niques. Diameter measurements were obtained from com-
puted tomography (CT) scan information or another
cross-sectional imaging tool (magnetic resonance imaging
or intravascular ultrasound). The proximal neck diameter
was measured immediately below the takeoff of the lowest
renal artery, and the length of the proximal neck was
determined by noting the distance from the lowest renal
artery to the beginning of the aneurysm (defined as a 10%
diameter increase over the immediate infrarenal segment).
Additional consideration in determining the proximal
neck length calculation included the presence of circum-
ferential thrombus or marked irregularities. Iliac diameter
measurements were obtained from the segment of iliac
artery where fixation and seal were targeted. The mini-
mum length of distal fixation was 20 mm. Maximum
aneurysm diameter was estimated from a single cross-
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Fig 1. Photographs show (A) an aortomonoiliac device, (B) a bifurcated customized device, and (C) a three-piece Zenith device.
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sectional image that appeared to represent the largest
aneurysm size. Length measurements were also calcu-
lated with a variety of techniques. Axial images, three-
dimensional reconstructions from CT scans, calibrated
angiography, and intravascular ultrasound were potential
additional sources of information. In many cases, a com-
bination of imaging modalities including angiography
and intravascular ultrasound scanning were used.
Fixation site prosthesis diameters were chosen to be
15% larger than the outer wall–to–outer wall measurement
of the cross-sectional image of the targeted segment.
Oversizing was performed in an effort to overcome the
potential errors in measurement, to accommodate from
slight expected aortic growth, and to allow the stents to
expand to the adventitial layer of the artery. The prosthe-
sis length was determined from CT scan reconstructions,
axial images, or calibrated angiography.
Three configurations of the device have been available
(Fig 1). Aortomonoiliac devices were initially used in all
patients but are now reserved for patients with unilateral
occlusive disease. The two-piece custom-designed system
requires one to accurately determine the ipsilateral limb
length, although some length flexibility is allowed with the
contralateral limb by tromboning the two pieces together.
The customized design is typically formulated in an effort to
cover as much of the arterial anatomy between the renal
arteries and the hypogastric artery as possible, which avoids
the consequences of late arterial degeneration. Finally, a
three-piece system has been developed to offer more flexi-
bility in the length measurements in both limbs (each limb
can be individually tromboned [or telescoped] into the main
body to preserve hypogastric flow). The main body portion
of the custom and three-piece device has been designed to
place the contralateral limb 15 mm above the aortic bifurca-
tion, with the ipsilateral (long) limb of the graft in the three-
piece device extending 15 mm into the ipsilateral common
iliac artery (in the custom device, the long limb extends up
to the hypogastric artery). The three-piece configuration
allows placement of the device at the level of the renal arter-
ies without regard for the hypogastric arteries, because the
ipsilateral common iliac limb cannot likely occlude this ves-
sel. Each of the iliac limbs may then be placed with a varying
overlap based on the main body length and its distance from
the respective hypogastric artery. This design allows one to
trombone the limbs slightly to adjust for length discrepan-
cies detected during the procedure. In addition, the joints
associated with this design are remote from the main
portion of the anuerysm sac thus, theoretically, should
be less effected by morphologic alterations.9 The disad-
vantage of such a system is the need for an additional
modular component.
Preoperative data collection included information on
patient demographics, American Society of Anesthesiology
(ASA) risk category, comorbid conditions, and aortic and
aneurysm morphologic condition. Implantation procedures
were performed in either an interventional suite or an oper-
ating room. The types of anesthesia included local,
epidural/spinal, and general. The choice of anesthestic was
dependent on physician preference. Intraprocedural data
points included duration of procedure, estimated blood
loss, and complications encountered. Length of stay, inten-
sive care unit stay, days of endotracheal intubation, and days
to ambulation were recorded. Postprocedural complications
were stratified into those that occurred within the first 30
days and those that occurred after the first 30 days. The
complications were categorized by body systems as follows:
cardiac, respiratory, vascular, neurologic, renal, and gas-
trointestinal and those complications related to cancer and
diabetes. Clinical follow-up protocols varied with the insti-
tution. Implantations performed in the United States were
followed with serial CT scans performed after the proce-
dure, 1 to 3 months, 6 months, 12 months, and yearly
thereafter. Those patients who underwent the procedure in
Europe and Australia underwent serial CT scans at a more
spaced interval, but studies were obtained at least yearly. A
radiologist or a vascular surgeon assessed the before and
after procedural images at each interval. Patients underwent
physical examinations and laboratory evaluation for serum
creatinine level, blood urea nitrogen level, and other
parameters at least yearly.
Endoleak information was determined by an assess-
ment of before and after contrast CT images obtained at
the various follow-up points. If present, leaks were fre-
quently further evaluated by angiography. The standard-
ized endoleak definitions proposed by the Sydney
group11,12 were used. However, the indications for treat-
ing endoleaks varied from center to center. All type I and
type III endoleaks were treated at the time of discovery,
providing the patient agreed to proceed. Type II leaks
were observed for the most part, intervening only in the
setting of aneurysmal growth. Migrations were detected
by CT scanning and further defined by angiography.
Careful attention was paid to the comparison between the
immediate postoperative view and follow-up images.
Changes in aneurysm size were carefully measured and
considered significant if the change was more than 5 mm.
Patients were followed clinically to evaluate groin
wounds, lower extremity circulation, aneurysmal disease
progression, and any symptoms or signs of rupture. Serum
creatinine and blood urea nitrogen levels were followed
closely. Every effort was made to explant the prosthesis in
the event of patient death to further assess wear and tear
and any in vivo histologic response.
RESULTS
A total of 528 patients have undergone the placement
of a Zenith endovascular prosthesis since 1995. The device
was initially developed and tested at the Royal Perth
Hospital; therefore, most of the long-term follow-up is
derived from Australian data. Subsequent involvement of
centers in Europe and the United States has increased the
database substantially, but the later experience is limited in
terms of follow-up. This database consists of 295 implan-
tations performed in Australia, 127 implantations per-
formed in European centers, and 106 implantations
performed in the USA . The mean patient age was 73
years, with 88% being male. Comorbid conditions and
demographic information are listed in Table I. Table II
lists the relative ASA risk categorizations.
Aneurysms were confined to the infrarenal abdominal
aorta in 76% of the patients, although 15% of the patients
had aneurysms that extended into one or both of the com-
mon iliac arteries. Only 1% of the patients treated with this
device had isolated iliac artery aneurysms. The mean
aneurysm size was 58.8 mm (range, 32-99 mm). The
mean proximal neck diameter was 23.4 mm (range, 14-31
mm). The mean length of the proximal neck was 26 mm.
Fig 2 depicts the relative distribution of neck lengths that
were treated.
Device configuration included a small number of aor-
toaortic tube grafts (2.5%), aortomonoiliac designs
(5.5%); most of the grafts were the bifurcated variety
(92%). Most of the procedures were performed with the
use of general anesthesia (68%), with a trend more
recently toward epidural or spinal anesthesia (23%). A rel-
atively small number of procedures were performed with
local anesthesia in unusual circumstances (6.3%). The
mean procedure duration was 155 minutes (range, 60-
510 minutes) with an estimated blood loss of 396 mL
(range, 50-800 mL). Complications detected during
device implantation are listed in Table III. There were four
conversions to open repair during the initial implantation
procedure, all of which occurred early in the study period.
Three of the conversions related to difficulty with access
vessels, and one conversion related to a deployment mech-
anism failure (inability to retrieve the top cap).
The mean intensive care unit stay after operation was
less than 1 day (0.45 days; range, 0->30 days), with 67%
of the patients never being admitted to the intensive care
unit. Almost 95% of the patients were either never intu-
bated or the endotracheal tube was removed during the
operative day. Just over 30% of the patients ambulated on
postoperative day 1, 30% on postoperative day 2, and the
remainder on day 3 or 4. The resumption of a regular diet
timing paralleled that of return to normal ambulation.
The mean length of hospital stay was 4.9 days (range, 1-
>15 days) with most of patients staying 4 days.
The mean follow-up time was 14 months (range, 0-36
months). However, imaging data were available within
this database for only 57% of the patients. The remaining
patients have imaging data at the respective centers; how-
ever, it was not available at the time of preparation of this
article. A total of 297 patients had follow-up information
from 0 to 90 days; 233 patients had more than a 1-year
follow-up, although 109 patients and 56 patients had
more than 2- and 3-year follow-up, respectively. The
imaging follow-up consisted of CT scans in 85% of the
patients. The remaining patients had duplex ultrasound
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Fig 2. The relative distribution of neck lengths for patients treated with the Zenith endovascular graft are shown.
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assessment of their aneurysm sac and endograft. Fig 3
depicts the aneurysm size during the follow-up period.
Significant decreases in aneurysm size were noted when
comparing those images obtained at each follow-up period
to the prior period (P < .05). Although renal complica-
tions were noted periprocedurally in just over 7% of the
population, there were no significant changes in the fol-
low-up blood urea nitrogen levels or the serum creatinine
levels. There were no renal complications attributed to the
placement of the suprarenal stent.
The overall endoleak rate varied depending on the fol-
low-up time. The initial postprocedural endoleak inci-
dence was 15%. This decreased to 5.5% after the first year
and to 1.7% after the second year of follow-up and rose to
4% during the latest follow-up period. The types of
endoleaks detected were varied. Type I endoleaks that
were detected in the immediate follow-up studies were
universally treated. The remaining identified leaks were all
classified as type II and were only selectively treated in the
setting of an increase in aneurysm size. Five cases of limb
thrombosis were noted. Most patients (3 of 5 patients)
were treated with femorofemoral cross-over grafts. The
remaining two patients were treated with thrombolytic
therapy, which restored patency in both cases.
Fig 4 is a Kaplan-Meier survival curve for the duration
of the follow-up period. A total of 48 patients died during
the follow-up period; two of these deaths were related to
aneurysm ruptures that occurred 6 and 850 days after the
implantation procedures. The first case was complicated
by a proximal endoleak that could not be resolved and was
felt to be too unstable to undergo an open surgical repair.
The aneurysm ruptured on postoperative day 6, and the
patient died before any intervention could be initiated.
The second death occurred more than 2 years after
implantation, and details were unavailable, but the death
certificate lists the cause of death to be a leaking
aneurysm. A third patient was treated for a contained rup-
ture in the setting of an endoleak with an additional
endovascular graft successfully. A total of eight patients
experienced endograft migration (>5 mm) during the fol-
low-up period. These were all noted between 2 and 3
years of follow-up. All of these patients had received early
iterations of the endovascular graft (without the current
barb design), and these events induced a change in endo-
graft design. There were three late conversions to open
repair; one conversion involved a patient with a device
migration. The other two conversions were performed in
patients who had symptoms that were potentially attrib-
uted to their abdominal aortic aneurysms, two of which
were associated with endoleaks and one was associated
with an endograft migration.
DISCUSSION
Careful consideration has gone into the design of both
the endograft and the delivery device. The evolution of
this device was influenced by early experiences that were
associated with many complications. For example, after
the implantation of non-fully supported Z-stent endo-
grafts into a group of patients, the Malmo group detected
a proximal stent migration rate of approximately 40%.2
The early migrations in the unsupported series of grafts
were attributed to a number of factors that included inad-
equate fixation mechanisms and improper device place-
ment in the perirenal aorta.4 It was observed that
“pre-Zenith” devices that were placed low in the proximal
neck had a higher incidence of migration, a high proximal
endoleak rate, and subsequent rupture. Patients treated
for aneurysms with open surgical and endovascular
approaches have been shown to undergo proximal neck
dilation over time.13-15 Potential explanations relate to the
instability of the infrarenal aorta in the setting of an
infrarenal aneurysm, which raised great concern among
Fig 3. Aneurysm size change over time is shown. The 0- to 90-day period represents a comparison of the preoperative image to the fol-
low-up image obtained before 90 days. The 90-day to 1-year group and the 2- to 3-year group show the sizes, with respect to the ini-
tial postoperative CT scan. Aneurysm expansion or contraction was not considered significant if it measured less than 5 mm.
the investigators and developers. The result was the devel-
opment of a mechanism to provide suprarenal aortic fixa-
tion and a delivery system that allows for extremely precise
positioning of the endograft at the level of the renal arter-
ies, similar to the surgical practice of suturing an anasto-
mosis in that region. However, this requires one to cross
the renal arteries with a bare stent; a practice that has
elicited a great deal of debate. A series of animal studies,16
in addition to the evaluations of many clinical implants,
has allowed advocates of suprarenal stenting to proclaim
this practice as safe.2,6,17,18 Other devices have used simi-
lar means of extension into the suprarenal aorta.19,20 Our
clinical follow-up demonstrates that renal function, as
assessed by blood urea nitrogen levels and creatinine lev-
els, is not impaired during the follow-up period and is in
agreement with several other studies.17,18 Furthermore,
no instance of renal artery occlusion has been observed to
be related to the presence of a suprarenal stent. The addi-
tion of barbs to the suprarenal stent was also intended to
diminish the incidence of migration. The fixation of the
prosthesis to the delivery device itself combined with a
separate mechanism used to deploy the barbs allows for
movement of the endograft after deployment of the graft
portion of the prosthesis. This allows the graft to be
placed just below the renal arteries, to optimize the “seal-
ing zone.”
Many of these modifications come at a cost. Although
suprarenal stenting is felt to be safe and effective by the
investigative cohort, secondary procedures can be slightly
more complex in this setting. Most of the investigators
have performed secondary renal interventions after
suprarenal stent placement without serious difficulties but
have found it better to address these renal issues from a
brachial approach. In addition, there are certain precau-
tions that must be recognized during device design when
systems with suprarenal stents are used. The angulation of
the suprarenal aorta must be viewed in context with angu-
lation of the proximal neck and the aneurysm sac.
Opposing angulations can result in the suprarenal segment
displacing the sealing stent in the infrarenal aorta, which
results in a proximal leak. For this reason, we do not advo-
cate the use of this graft in the setting of an angulated
suprareanal aorta that opposes the angle of the infrarenal
aorta. Experience with suprarenal stents has not been lim-
ited to the Zenith endograft. The Talent19 and
Montifiore20 devices also rely on partial fixation in the
suprarenal aorta.
The aortic penetration by barbs may incite some con-
cern, specifically in regard to malpositioning of the endo-
graft. In two instances in which the device was deployed
too high, a wire was passed over the aortic bifurcation, and
the endograft was pulled down with some difficulty. There
is concern for aortic damage with this technique, and thus
it is not advised. Another means of achieving renal artery
patency was used in two patients. Renal stents were placed
to push the graft material away from the renal artery ori-
fice when graft material was inadvertently placed over one
or both renal artery orifices. This technique worked well
but should be done with a brachial approach. The addi-
tional control during deployment conferred by the deliv-
ery system should minimize this problem.
Conversion to open repair in the setting of suprarenal
fixation with barbs has been performed in three patients in
this series. All cases required supraceliac clamping to avoid
damaging the aortic wall by crushing the stent material.
After an aortotomy, an umbilical tape was tightened at the
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Fig 4. Kaplan-Meier curve plots survival over time. Care should be taken when evaluating the longer implant dates because they relate
to early devices and small numbers of patients.
Time (months)
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infrarenal component of the suprarenal stent in one case,
and the stent was pulled out without much difficulty, by
forcing the barbs to bend upwards. Perhaps a simpler solu-
tion was exercised in two other cases in which the graft
material was transected and removed, leaving the
suprarenal stent in place without any graft material. The
proximal anastomosis was then constructed in such a man-
ner to incorporate the suprarenal stent. Although one can
argue that the presence of barbs may complicate explanta-
tion procedures, designing an implant so that it is more
easily removable would likely increase the risk of migration
during the lifetime of the patient. The displacement force
of the endograft was tested in a cadaver model with a vari-
ety of hook and barb configurations.21 The findings of this
study supported the use of larger and more numerous
barbs. This coincided with the clinical findings in three
patients who experienced endograft migration when a sys-
tem with only four weak barbs was used. The subsequent
addition of more barbs (to bring the total to ten)
increased the required displacement force in the cadaver
model, and no clinical migrations have been detected with
the use of this configuration to date.4,22,23 However, it is
difficult to state this without some reservations, given the
relatively short follow-up period. There have been no barb
breakages noted on radiographic follow-up throughout
the study.
The preoperative aortic morphologic condition in this
patient population was quite varied. Investigations limited
procedures to patients with aortic diameters equal to or
less than 28 mm. The reasons for this relate to observa-
tions that indicate the potential rapid growth of the aortic
diameter in the larger aortic neck.13,14 In addition, despite
the added fixation the Zenith graft has in the suprarenal
aorta, we have been quite conservative with regard to neck
length. Most patients had proximal neck lengths greater
than 20 mm. This conservative approach was chosen to
ensure an adequate sealing zone and to exclude patients
who actually have pararenal aneurysms.
This patient series noted five cases of limb throm-
boses. Earlier work with incompletely supported systems24
had a much higher number of limb thromboses, and the
earlier system was redesigned on the basis of those experi-
ences. However, limb kinking is still possible with extreme
angulation and severely diseased external iliac arteries
increase this risk. The current rate is relatively low (<1%)
and appears to parallel other contemporary endograft
series. On the other hand, the design of the modular junc-
tion is significantly different in comparison with competi-
tive devices. The main body of the device is longer than
other endografts, designed in such a manner to bring the
contralateral limb closer to the contralateral iliac artery.
This serves to simplify cannulation and the insertion of the
contralateral limb and brings the contralateral junction
away from the largest portion of the aneurysm sac, avoid-
ing limb dislocation as the result of dimensional changes
in the excluded aneurysm.
The postoperative data in this series are similar to
other multicenter international trials. There is great vari-
ability in the length of stay data, depending on the coun-
try. For example, the mean length of stay in the United
States of patients with Zenith implants was 2.3 days,
although in Australia and Europe it was closer to 5 days.
It was infrequent to keep patients intubated for prolonged
periods of time. The estimated blood loss was comparable
to contemporary endograft series and markedly decreased
with improvements in the hemostatic valve system on the
delivery sheaths.
Finally, the follow-up imaging data are incomplete
because of difficulties compiling data from a variety of
databases. In addition, these long-term data are heavily
influenced by the Australian implantations. The aneurysm
size clearly decreases in most cases during the follow-up
period. The long-term results appear positive; however, at
this point in time, the aneurysms are protected from sys-
temic pressures. This information coincides with diminish-
Table I. Demographic and comorbid patient information
Percentage
Cardiovascular 41
Respiratory 31
Vascular 29
Neurologic 12
Renal 12
Blood disorder 5
Gastrointestinal 5
Cancer 2
Diabetes 2
Other 58
Table III. Complications associated with or detected
during the initial implantation procedure
Complication Percentage
Endoleak 16.3
Iliac access 13.9
Cardiovascular 7.0
Extension pieces required 5.5
Physician technical issues 3.1
Vascular/arterial problems 1.0
Deployment system 1.0
Immediate migration 1.9
Table II. ASA risk categories
Category Percentage
I 2
II 32
III 57
IV 9
ing endoleak rates. However, the slight increased inci-
dence from 1.9% to 4% (not statistically significant) may
be concerning, although one must remember that the
device has evolved considerably during this time frame.
Alternatively, the late endoleaks have arisen from patients
who underwent implantations early in our experience,
thus we expect this rate to decrease over time. Despite
decreasing aneurysm size, the development of a late
endoleak is extremely worrisome and may actually predis-
pose a patient to a higher risk of rupture than the previ-
ously untreated aneurysm. The two late ruptures that
were observed were both in the setting of endoleaks and
thus support this concern. The early rupture associated
with a death is the result of a technical failure in a patient
with an unstable condition. Efforts to ensure the stability
of this graft have included a secure fixation mechanism,
the use of stainless-steel well-defined stents, and thick-
walled graft material.
The placement of the Zenith endovascular graft can
be accomplished with minimal morbidity and death. The
patients have relatively short hospital stays and minimal
blood loss and return to normal function quickly.
Aneurysm size appears to decrease in most cases during
the follow-up period, and rupture is rare; however, the
potential for late endoleaks has not been eliminated.
Graft failure and metal fatigue are possible and have been
noted with other devices. We feel we have minimized this
risk by using time-tested prosthetic materials, in a man-
ner that closely resembles our practices of open surgical
repair.
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